Dr. Abokhair Algahmi

Consultant of Medical Oncology

14 : 20 – 14 : 30

23 June | 2023 Day 1

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)

4th PSMMC ASCO Data Review Meeting (PADRM). This meeting will highlight the top most clinically relevant achievements of ASCO 2023 for different and commonest tumor types.